Tyrosine kinase inhibitors' blood level monitoring and response to treatment in patients with Chronic Myeloid Leukemia for population characterization of patients and correlation between the evaluated parameters and disease evolution.

• Grant number: 15/23091-7
• Support Opportunities: Regular Research Grants
• Start date: November 01, 2016
• End date: April 30, 2020
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Israel Bendit
• Grantee: Israel Bendit
• Host Institution: Hospital das Clínicas da Faculdade de Medicina da USP (HCFMUSP). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil
• Associated researchers: Vinicius Marcondes Rezende

Abstract

Several studies have suggested that treatments with decreasing imatinib mesylate's dosing, starting in 800 mg / day to 400 mg / day present better response to treatment of chronic phase CML. These results have been obtained by monitoring blood levels of imatinib and comparison to response indicators to imatinib or other TKI, as Hematologic Response (HR) Cytogenetic Response (CR) and Molecular Response (RM) BCR-ABL / control gene [Larson, 2008]. Thus, there are evidences that the evaluation of the relationship between the dose of imatinib or other ITQ (as well as blood levels) and the effectiveness of treatment, as measured by the cytogenetic and molecular responses, is a way to make the adjustment of the dose reducing side effects, and cost of treatment. This study aims to obtain blood levels data of the drugs and the molecular response in the population, in an attempt to relate the two results in the study population, in order to promote the correct dose adjustment. (AU)